



#9.  
da  
5/15/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Christopher P. Adams, Jr.  
Joseph D. Kittle, Jr.

Filed: November 15, 2001  
Serial No.: 09/857,378

For: Method for the Immobilization  
of Oligonucleotides

§  
§  
§  
§  
§  
§  
§  
§  
§  
§  
§

Art Unit: 1632

Examiner: Scott David Priebe

Attorney Docket No.: 019896-00401

RECEIVED

MAY 14 2003

TECH CENTER 1600/2900

MAIL STOP DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO RESTRICTION REQUIREMENT  
AND OFFICE ACTION OF MARCH 7, 2003**

Dear Sir:

This communication is in response to the Office Action dated 7 March 2003, requiring restriction under 35 U.S.C § 121.

**REMARKS:**

**Requirement for Restriction.** The Examiner has required restriction under 35 U.S.C § 121 and 372 among the following claims:

**Group I.** Claims 1-57, drawn to a polymer made with a sub-unit comprising a nucleic acid and an ethylene-containing moiety; and

**Group II.** Claims 58-65, drawn to a pharmaceutical formulation and a method for introducing a nucleic acid into a cell of an animal *in vivo*, wherein the nucleic acid is part of a polymer made with a sub-unit comprising a nucleic and an ethylene-containing moiety.

Applicants elect claims 1-57 which represent Group I, with traverse.

The Examiner states that "Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1, because, under PCT Rule 13.2 . . . . Boles et al., US 5,932,711 discloses polymers readable on the invention of Group I." (Last two paragraphs on page 2 of